Bioptigen, Inc., has been approved to market its eye-imaging system in European Union countries, the company said.
“Earning a CE Mark is an important milestone for Bioptigen, but it’s even more meaningful for the pediatric and adult patients who now can benefit from our more flexible imaging platform. We bring imaging to the patient; the patient doesn’t have to come to us,” Dr. Eric Buckland, president and CEO, said. “Knowing that Bioptigen can improve the quality of life for patients is extremely rewarding.”
The approval is for Bioptigen’s Envisu C2000 technology.
The Envisu system employs low-power, near-infrared light to generate real-time, high-resolution, depth-resolved images of eye structures.
Get the latest news alerts: Follow WRAL Tech Wire at Twitter.
